Merck Adds Phase II Oncology Candidate Via Acquisition Of Aton
Executive Summary
Merck will have a Phase II oncologic drug candidate after completing the acquisition of privately held Aton Pharma
You may also be interested in...
Biotech Exit Strategy Of Choice Is Acquisition, Not IPO, Investor Says
Venture capital firms are increasingly shaping biotech companies to look like acquisition prospects from the outset, rather than candidates for initial public offerings, according to one investor's analysis
Biotech Exit Strategy Of Choice Is Acquisition, Not IPO, Investor Says
Venture capital firms are increasingly shaping biotech companies to look like acquisition prospects from the outset, rather than candidates for initial public offerings, according to one investor's analysis
Merck To Increase Internal R&D But Reduce Outside Deals In 2005
Merck expects to decrease its spending on product acquisition and licensing deals in 2005, the company told analysts during its Dec. 14 annual business review in Whitehouse Station, N.J